Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia.

  title={Blockade of Fas-dependent apoptosis by soluble Fas in LGL leukemia.},
  author={J. Liu and S. Wei and T. Lamy and Y. Li and P. Epling-Burnette and J. Djeu and T. Loughran},
  volume={100 4},
  • J. Liu, S. Wei, +4 authors T. Loughran
  • Published 2002
  • Biology, Medicine
  • Blood
  • Altered expression of the Fas-Fas ligand apoptotic pathway leads to lymphoproliferative and autoimmune diseases. In lpr/lpr mice and children with autoimmune lymphoproliferative syndrome, defective apoptosis is due to Fas mutations. Large granular lymphocyte (LGL) leukemia is a clonal lymphoproliferative disorder associated with rheumatoid arthritis. Leukemic LGLs are resistant to Fas-dependent apoptosis despite expressing high levels of Fas. Such resistance can be overcome by activating… CONTINUE READING
    88 Citations
    CD95 (APO‐1/FAS) deficiency in infant acute lymphoblastic leukemia: detection of novel soluble Fas splice variants
    • 20
    Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets.
    • 29
    LGL leukemia: from pathogenesis to treatment.
    • 77
    • PDF
    Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment.
    • 63
    • PDF
    Dysfunction of immune system in the development of large granular lymphocyte leukemia
    • 8
    Long noncoding RNA Saf and splicing factor 45 increase soluble Fas and resistance to apoptosis
    • 33
    • PDF
    The pathogenesis and treatment of large granular lymphocyte leukemia.
    • 54


    Expression of the Fas ligand in cells of T cell lineage.
    • 704
    Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule.
    • 1,130
    Fas and FasL in the homeostatic regulation of immune responses.
    • 613